- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.12.25 | UK agrees to boost drug prices to dodge US pharma tariffs | ||
| 01.12.25 | Regeneron inks gene editing deal with startup Tessera | ||
| 01.12.25 | Belite continues ascent as Stargardt drug hits mark in late-stage trial | ||
| 01.12.25 | With $130M, Protego pushes forward a new type of amyloidosis drug | ||
| 01.12.25 | From feedstocks to infrastructure, Indiana's bioeconomy is on the move | ||
| 01.12.25 | Specialty pharmacy's secret weapon: The unsung power of the enrollment form | ||
| 01.12.25 | Expanding access in oncology trials: The case for a paired tissue-plasma approach | ||
| 26.11.25 | Otsuka gains approval for first-of-its-kind treatment against rare kidney disease | ||
| 26.11.25 | Novartis cuts hundreds of jobs; Novo's dual-acting diabetes drug heading to Phase 3 | ||
| 26.11.25 | CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs | ||
| 25.11.25 | Novartis wins approval to use SMA gene therapy in older patients | ||
| 25.11.25 | Gilead scoops up a preclinical cancer program | ||
| 25.11.25 | How do Big Pharma employees rate their CEOs? | ||
| 24.11.25 | Bayer's experimental blood-thinner notches trial win in stroke prevention | ||
| 24.11.25 | Novo Nordisk's GLP-1 misses goal in closely watched Alzheimer's studies | ||
| 24.11.25 | FDA probes effects of Takeda rare disease drug after patient death | ||
| 24.11.25 | APOE4 and CRISPR are reframing Alzheimer's Risk | ||
| 21.11.25 | Eli Lilly becomes first drugmaker to hit $1 trillion in market value | ||
| 21.11.25 | GSK, Anaptysbio sue each other over Jemperli revenue | ||
| 21.11.25 | FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M | ||
| 21.11.25 | A brain biotech's top drug fails against MS | ||
| 20.11.25 | Moderna secures $1.5B lifeline as it looks to break even in 2028 | ||
| 20.11.25 | Aspen raises $115M for a Parkinson's stem cell treatment | ||
| 20.11.25 | Abbott to acquire Exact Sciences for about $21B | ||
| 20.11.25 | With new approvals, Regeneron's higher-dose Eylea gets more competitive |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.